Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML
Jad Othman(The University of Sydney), Richard Dillon(King's College London), Yanis Tazi(Memorial Sloan Kettering Cancer Center), Claire Arnold(University of Ulster), Jelena Jovanović(Centre de Recherche Jean Pierre Aubert), Tanya Rapoz-D’Silva(London Cancer), Pawan Dhami(Guy's and St Thomas' NHS Foundation Trust), Adam Ivey(The Alfred Hospital), Sean Johnson(Cardiff University), Panagiotis Kottaridis(University of Oxford), Amanda Gilkes(Cardiff University), Sylvie Freeman(University of Birmingham), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Manohursingh Runglall(King's College London), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Mike Dennis(The Christie NHS Foundation Trust), Michelle Kleeman(Guy's and St Thomas' NHS Foundation Trust), Rosemary E. Gale(London Cancer), Joanna Canham(Cardiff University), Ian Thomas(Cardiff University), Ulrik Malthe Overgaard(Copenhagen University Hospital), Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center), Hans Beier Ommen(Centre de Recherche Jean Pierre Aubert), Nicola Potter(European Bioinformatics Institute), Alan Burnett(University of Glasgow), Jamie Cavenagh(St Bartholomew's Hospital), Charlotte S. Wilhelm-Benartzi(Cardiff University)
Cited by 78
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k